Welcome to our dedicated page for Precipio news (Ticker: PRPO), a resource for investors and traders seeking the latest updates and insights on Precipio stock.
Precipio Inc (PRPO) delivers innovative cancer diagnostics through advanced testing technologies and strategic research partnerships. This news hub provides investors and healthcare professionals with essential updates on the company's progress in personalized medicine and laboratory services.
Access official press releases covering financial results, diagnostic product launches, and collaborations with leading medical institutions. Our curated collection ensures timely updates on regulatory milestones, clinical validation studies, and operational developments within Precipio's CLIA-certified laboratories.
Key focus areas include advancements in blood cancer diagnostics, molecular testing innovations, and partnerships enhancing precision oncology. All content maintains strict compliance with financial disclosure standards, offering neutral reporting on material business developments.
Bookmark this page for streamlined access to Precipio's latest announcements, or check back regularly for updates impacting the oncology diagnostics sector. For historical context, explore archived releases demonstrating the company's ongoing commitment to reducing diagnostic errors in cancer care.
Precipio, Inc. (NASDAQ: PRPO) reported Q1-2023 product revenues of approximately $0.76M, exceeding the combined revenues of $0.66M from Q3 and Q4 of 2022. This marks a notable increase, achieving over 50% of the total product revenues for the entire year of 2022, which were $1.4M. The annualized run rate currently stands at $3M, more than doubling 2022's total revenues. The growth is attributed to the company’s successful strategy of converting prospects into signed customers. The CEO, Ilan Danieli, highlighted that consistent revenue growth will lead to reduced cash burn and a path towards profitability. It is crucial to note that these figures are preliminary and unaudited, with complete financials expected by May 15.
Precipio, Inc. (NASDAQ: PRPO) plans to host a Q4-2022 and year-end shareholder update call on April 3, 2023, at 5:00 PM ET. This call will provide updates on the company’s core businesses and is accessible via a phone call or pre-registration online. Precipio aims to improve diagnostic accuracy in cancer care through collaborations with academic institutions. The press release includes forward-looking statements regarding the company’s business and warns of various risks, particularly concerning the ongoing COVID-19 pandemic.
FAQ
What is the current stock price of Precipio (PRPO)?
What is the market cap of Precipio (PRPO)?
